A 65-year-old man with hypertension and lower urinary tract symptoms (LUTS) secondary to BPH has been on doxazosin 4 mg daily for 3 months with good symptom control and BP reduction to 135/82 mmHg. He now presents with persistent orthostatic dizziness, fatigue, and a resting heart rate of 110/min. Orthostatic vital signs show a drop of 22 mmHg systolic on standing. What is the most appropriate next step?

Explanation

## Clinical Problem: Chronic Orthostatic Hypotension on Alpha Blocker **Key Point:** Persistent orthostatic symptoms and reflex tachycardia after 3 months of alpha blocker therapy indicate **chronic vasodilatory adverse effect** rather than first-dose syncope. The patient requires a switch to a **uroselective alpha blocker** (tamsulosin or alfuzosin) to maintain BPH efficacy while minimizing systemic vasodilation. **High-Yield:** Non-selective alpha blockers (doxazosin, terazosin) block both α~1a~ (vascular) and α~1b~ (urological) receptors. Uroselective agents (tamsulosin, alfuzosin) preferentially block α~1a~ in the prostate, sparing vascular α~1b~ receptors → less orthostasis. ## Comparison: Alpha Blockers in BPH | Agent | Selectivity | Vasodilation | Orthostasis Risk | Dosing | |-------|-------------|--------------|------------------|--------| | **Doxazosin** | Non-selective | Marked | High (10–15%) | 1–8 mg daily | | **Terazosin** | Non-selective | Marked | High (10–15%) | 1–20 mg daily | | **Tamsulosin** | α~1a~-uroselective | Minimal | Low (3–5%) | 0.4–0.8 mg daily | | **Alfuzosin** | α~1a~-uroselective | Minimal | Low (3–5%) | 2.5–10 mg daily | **Clinical Pearl:** Tamsulosin is the preferred agent for patients with concurrent hypertension and orthostatic intolerance because it achieves LUTS relief without additional BP lowering. ## Management Decision Tree ```mermaid flowchart TD A[Patient on non-selective alpha blocker with persistent orthostasis]:::outcome --> B{Adequate LUTS control?}:::decision B -->|Yes| C[Switch to uroselective agent]:::action B -->|No| D[Increase non-selective dose]:::action C --> E[Tamsulosin or alfuzosin]:::action D --> F[Monitor for worsening orthostasis]:::action E --> G[Reassess symptoms in 4 weeks]:::action ``` **Tip:** Orthostatic symptoms often persist or worsen with dose escalation of non-selective agents; switching class is more effective than dose reduction in this scenario. [cite:KD Tripathi 8e Ch 10; Harrison 21e Ch 246]